Physical Inactivity, Pulmonary Arterial Hypertension
Conditions
Keywords
pulmonary arterial hypertension, education, self-monitoring, physical activity, step count
Brief summary
Evaluate whether education, a simple doctor's recommendation to increase physical activity in inactive patients, and self-monitoring of physical activity using a pedometer were effective and beneficial for patients with pulmonary arterial hypertension (PAH)
Detailed description
Each patient was educated about the benefits of PhA in PAH on the initial visit. Patients wore pedometers (Omron HJ-321-E) for 2 weeks. After PhA assessment, the patients were contacted by a physician. Patients who walked \<5,000 steps per day were recommended to increase PhA, and patients who walked ≥5,000 steps per day were recommended to maintain PhA. Patients wore pedometers for 3 months until their next visit. The primary endpoint was the number of steps after 12 weeks of the study; the secondary endpoint was the 6-minute walk test distance (6MWD), quality of life (SF-36), acceptance of the disease, and anxiety and depression level (HADS).
Interventions
BEHAVIORALrecommendation to increase physical activity
education on the benefits of physical activity in PAH from the first visit and doctor's recommendation to increase physical activity above 5,000 steps a day in inactive patients and above 5,000 steps per person in active patients
Sponsors
Centre of Postgraduate Medical Education
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age equal to or greater than 18 years * PAH diagnosis according to current guidelines, confirmed by right heart catheterization * optimal pharmacological treatment * stable clinical condition at least 3 months before inclusion in the study * Informed consent to participate in your own
Exclusion criteria
* Age under 18 years * a type of hypertension other than PAH * a neurological or orthopedic disease that prevents walking and performing the 6-minute walk test * mental illness that prevents cooperation and assessment of quality of life survey * lack of consent to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of steps per day | At baseline, after initial period 2 weeks | Number of steps per day monitored by pedometer Omron HJ-321-E |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in quality of life (SF-36) | At baseline, 3 months | Change in quality of life recorded by patient questionnaire 36-Item Short Form Health Survey (SF-36) |
| Change in the hospital anxiety and depression scale (HADS) | At baseline, 3 months | level of anxiety and depression measured by hospital anxiety and depression scale (HADS) |
| Change in the acceptance of illness (AIS) | At baseline, 3 months | acceptance of illness measured by acceptance of illness scale (AIS) |
| Change in 6-minute walk distance | At baseline, 3 months | Distance in six-minute walk test |
| Change in World Health Organization (WHO) functional Class recorded by investigator in conjunction with the 6MWD | At baseline, 3 months | WHO functional class assessment |
| Compliance with counting steps | at 3 months | Compliance with counting steps |
| Change in N-Terminal Pro-B-Type Natriuretic Peptide level (NT-proBNP) | At baseline, 3 months | Blood sample to measure the concentration of N-terminal Pro-B type natriuretic peptide |
Countries
Poland
Outcome results
None listed